Navigation Links
Senesco Announces H1N1 Influenza Survival Test Results in Mice
Date:5/26/2009

NEW BRUNSWICK, N.J., May 26 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported results of H1N1 mouse influenza survival studies that were conducted in Dr. William Scheld's lab at the University of Virginia School of Medicine. Mice treated with an siRNA against Senesco's Factor 5A gene had a 52% survival rate as opposed to a 14% survival rate for mice that received no treatment or a control siRNA.

A total of 73 mice were infected with a lethal dose of nasally administered H1N1 mouse influenza. The treated mice (n=31 mice) were administered Senesco's siRNA against Factor 5A approximately 24 hours after infection and then every other day for 11 days. Treated mice reversed the weight loss typically seen in infected mice at around day 8 of the study, which coincides with the reduced mortality. The treated mice had other reduced indicators of disease severity as measured by blood glucose and liver enzymes.

Dr. Scheld, the Bayer-Gerald L. Mandell Professor of Internal Medicine at the University of Virginia School of Medicine and past president of the Infectious Diseases Society of America, commented, "These prototype studies have demonstrated that Factor 5A is a promising candidate for future study in several infectious diseases, including a model of lethal influenza."

Bruce Galton, Senesco's President and CEO, added, "We believe these data from Dr. Scheld further underscore Factor 5A's ability to mitigate apoptosis caused by inflammation, in this case from the H1N1 flu model. As we have previously stated, one of the attributes of Senesco's Factor 5A technology is its broad applicability. While we are currently working on our primary goal of filing an investigational new drug application with the FDA for the treatment of multiple myeloma, it is important that our other inflammation programs also progress."

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate a financing; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to continue to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

    Company Contact:
    Senesco Technologies, Inc.
    Bruce Galton
    Chief Executive Officer
    bgalton@senesco.com
    (732) 296-8400

    Investor Relations Contact:       Media Relations:
    FD                                FD
    Brian Ritchie                     Irma Gomez-Dib
    brian.ritchie@fd.com              irma.gomez-dib@fd.com
    212-850-5600                      212-850-5600


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Senesco Chooses VGXI to Produce Factor 5A Plasmid
2. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
3. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
4. Senesco Technologies Initiates Preclinical Studies for Cancer Target
5. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
6. Telik Announces Presentation at ASCO Annual Meeting
7. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
10. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
11. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... , May 11, 2017  Thornhill Research Inc. ... been awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery ... the Canadian Commercial Corporation (CCC) ( Ottawa, ... Systems to administer general anesthesia to patients requiring ... "The US Marine Corps have been a ...
(Date:5/10/2017)... 2017 CSSi, the global leader in patient ... industry, is proud to announce the launch of its ... features both enriched content and a customized layout that ... company,s already well-established position as the top global patient ... many months of hard work, we are delighted to ...
(Date:5/8/2017)... 8, 2017 MACRA replaces the outdated ... for service reimbursement. Black Book Research crowdsource-surveyed 8,845 physician ... 1.       The Market for MIPS Compliance Technology is Booming ... practices with 3 or more clinicians seek to buy ... "Given the magnitude of the changes, the hunt is ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... ... “Just What Happened in the Garden of Eden”: retells the stories of three Bible figures ... of published author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. ... three. At six, they moved to Dayton, Ohio, where Penny graduated high school. ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... background. Understanind and choosing the most appropriate instruments for research and understanding the ... research finding. This webinar will focus on innovations in stereo microscopy for brightfield ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... Bayside, NY, who have now spent 10 years as clinical instructors for the ... (NYU) College of Dentistry. Through the program, private practitioners receive cutting-edge clinical training ...
(Date:5/24/2017)... ... 24, 2017 , ... Myers Jackson is well known for auctioning homes that ... homes anywhere on the planet. The luxury home market is alive and well and ... A quick search of “11 Spyglass Hill Auction will enlighten you on the dynamics ...
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant Technology, a ... portfolio. ExtraHop delivers an analytics-first approach, layered with machine learning, that provides real-time ... datacenter to the cloud to the edge. Through the new partnership, customers get ...
Breaking Medicine News(10 mins):